DEERFIELD MANAGEMENT COMPANY, L.P. 4

What Happened

• James E. Flynn, reported as a 10% owner through Deerfield-managed funds, acquired a total of 5,000,000 shares of Larimar Therapeutics (LRMR) on 2026-02-27. The purchases were made in four transactions of 1,084,010; 1,084,012; 831,978; and 2,000,000 shares, each at $5.00 per share, totaling $25,000,000. Transaction code: P (purchase). Purchases are generally viewed as a more informative (bullish) insider signal than sales, though no motive is stated.

Key Details

• Transaction date: 2026-02-27; Filing date: 2026-03-02 (timely Form 4 filing).
• Price and amounts: 5,000,000 shares at $5.00 each = $25,000,000 total (broken into four lots: 1,084,010; 1,084,012; 831,978; 2,000,000).
• Shares owned after transaction: not specified in this Form 4 (the filing reports holdings of the Funds collectively).
• Footnotes/notable parties:
  • The filing is made on behalf of multiple Reporting Persons (Deerfield funds and management entities). Flynn is the sole manager of the general partners of the Deerfield entities listed (see footnotes).
  • Footnote disclaims direct beneficial ownership by the Reporting Persons except for indirect pecuniary interests (institutional ownership via funds).
  • Jonathan S. Leff (a Deerfield partner) serves as a director of Larimar; Jonathan Isler is listed as attorney-in-fact.
• Transaction code: P = Purchase.

Context

• These purchases were made by funds managed by Deerfield (institutional/10% owner activity). That means the transactions represent fund-level acquisitions under Flynn’s management rather than necessarily personal trades by Flynn.
• No options, awards, gifts, or tax-withholding actions are reported here—just open-market/private purchases.